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Nuclear receptors PPARβ/δ and
PPARα direct distinct metabolic
regulatory programs in the mouse heart
Eileen M. Burkart,1,2 Nandakumar Sambandam,1,2 Xianlin Han,2
Richard W. Gross,2,3 Michael Courtois,1,2 Carolyn M. Gierasch,1,2
Kooresh Shoghi,3,4 Michael J. Welch,3,4 and Daniel P. Kelly1,2,3,5
1Center

4Department

for Cardiovascular Research, 2Department of Medicine, 3Department of Molecular Biology and Pharmacology,
of Radiology, and 5Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.

In the diabetic heart, chronic activation of the PPARα pathway drives excessive fatty acid (FA) oxidation, lipid
accumulation, reduced glucose utilization, and cardiomyopathy. The related nuclear receptor, PPARβ/δ, is also
highly expressed in the heart, yet its function has not been fully delineated. To address its role in myocardial
metabolism, we generated transgenic mice with cardiac-specific expression of PPARβ/δ, driven by the myosin
heavy chain (MHC-PPARβ/δ mice). In striking contrast to MHC-PPARα mice, MHC-PPARβ/δ mice had increased
myocardial glucose utilization, did not accumulate myocardial lipid, and had normal cardiac function. Consistent with these observed metabolic phenotypes, we found that expression of genes involved in cellular FA transport were activated by PPARα but not by PPARβ/δ. Conversely, cardiac glucose transport and glycolytic genes
were activated in MHC-PPARβ/δ mice, but repressed in MHC-PPARα mice. In reporter assays, we showed that
PPARβ/δ and PPARα exerted differential transcriptional control of the GLUT4 promoter, which may explain the
observed isotype-specific effects on glucose uptake. Furthermore, myocardial injury due to ischemia/reperfusion injury was significantly reduced in the MHC-PPARβ/δ mice compared with control or MHC-PPARα mice,
consistent with an increased capacity for myocardial glucose utilization. These results demonstrate that PPARα
and PPARβ/δ drive distinct cardiac metabolic regulatory programs and identify PPARβ/δ as a potential target for
metabolic modulation therapy aimed at cardiac dysfunction caused by diabetes and ischemia.
Introduction
We are witnessing a pandemic of obesity-related diabetes (1). Diabetes predisposes to heart failure, particularly in combination with
other comorbid conditions such as hypertension and coronary
artery disease (2, 3). The incidence of heart failure and death following myocardial infarction is higher in diabetic than in nondiabetic individuals (4–9). Evidence is emerging that derangements in
cardiac fuel metabolism, related to insulin resistant and diabetic
states, contribute to the development of diabetic cardiac dysfunction. The normal adult heart satisfies its energy requirements
through the oxidation of both fatty acids (FAs) and glucose (10, 11).
However, myocardial insulin resistance and increased rates of systemic lipolysis force the diabetic heart to rely almost exclusively
on FA as a fuel source, a loss of substrate flexibility (12–14). Over
the long term, high rates of myocardial FA utilization predispose
to the development of a “lipotoxic” form of cardiomyopathy, characterized by myocyte lipid accumulation, mitochondrial dysfunction, and generation of reactive oxygen species related to excessive
substrate flux (12–16). In addition, the diabetic heart has a reduced
capacity for glycolysis and glucose oxidation, which predisposes to
postischemic damage (17, 18).
Nonstandard abbreviations used: 2-DG, 2-deoxyglucose; ESI/MS, electrospray
ionization mass spectrometry; FA, fatty acid; FAO, FA oxidation; FS, fractional shortening; HE, high expression; HF, high fat; IA/AAR, infarcted area relative to area at risk;
I/R, ischemia/reperfusion; LE, low expression; ME, medium expression; MHC, myosin
heavy chain; NTG, nontransgenic; TAG, triacylglyceride.
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Recent evidence has implicated dysregulation of the nuclear
receptor PPARα (Ppara) in the metabolic and functional derangements of the diabetic heart (19, 20). PPARα activates transcription
of genes involved in cellular lipid utilization pathways, including FA uptake and FA oxidation (FAO) (21, 22). The PPARα gene
regulatory pathway is chronically activated in the hearts of insulin-deficient and insulin-resistant rodents (19). Transgenic mice
with cardiac-specific overexpression of PPARα (MHC-PPARα
mice) display a functional and metabolic phenotype that mimics
the diabetic heart (19). Specifically, MHC-PPARα mouse hearts
exhibit increased FAO rates, decreased glucose utilization, myocyte triacylglyceride (TAG) accumulation, and cardiomyopathy.
Interestingly, the lipotoxic cardiomyopathy of MHC-PPARα mice
is worsened with consumption of a high-fat (HF) diet (20). Consistent with observations in animal models, recent studies using
PET have shown that hearts of diabetic humans exhibit increased
FA uptake and utilization rates (19, 23, 24).
PPARα is a member of a FA-activated nuclear receptor family
that includes PPARγ (Pparg) and PPARβ/δ (Ppard) (21). In contrast to PPARγ, which is adipose enriched, PPARβ/δ is highly
expressed in cardiac myocytes, similar to PPARα (25). Whereas the
function of PPARα has been the subject of intense investigation,
less is known about PPARβ/δ. Mice with cardiac-specific deletion
of the PPARβ/δ gene were recently shown to develop myocardial
lipid accumulation and cardiomyopathy (26). These results suggest that PPARβ/δ is necessary for myocardial lipid homeostasis.
However, the biologic response and corresponding gene activation
profiles following activation of the PPARβ/δ pathway, compared
with PPARα, have not been fully delineated.
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Figure 1
Generation of MHC-PPARβ/δ mice. (A) Top: Representative autoradiographs of Northern blot analyses performed with RNA isolated from
hearts of 8-week-old mice from independent MHC-PPARβ/δ–LE, MHCPPARβ/δ–ME, and MHC-PPARβ/δ–HE lines. At the exposure shown,
endogenous (endo) PPARβ/δ was not detected in NTG samples. Note
that the endogenous PPARβ/δ transcript was induced in the transgenic
heart (lower band). The 28s rRNA is shown as a loading control. Bottom: Representative Western blots performed with protein isolated
from cardiac ventricles of MHC-PPARβ/δ–LE and MHC-PPARβ/δ–HE
mice. The nonspecific signal is shown as a control for loading. (B) Representative Northern blot showing the expression of known PPARα
target genes in hearts of MHC-PPARβ/δ–ME and MHC-PPARβ/δ–HE
mice. The 36B4 signal is shown as a loading control.

To investigate the role of PPARβ/δ in the regulation of heart
metabolism and function, we generated and characterized transgenic mice with cardiac-specific expression of PPARβ/δ (MHCPPARβ/δ mice). Surprisingly, in contrast to MHC-PPARα mice,
MHC-PPARβ/δ mice did not develop cardiomyopathy and exhibited a strikingly different cardiac fuel preference. This PPAR
isotype–specific response was also observed following ligandmediated activation of the endogenous nuclear receptors. The
PPAR-specific effects on cardiac metabolism were dictated by both
shared and distinct gene targets. Most notably, PPARβ/δ activated,
whereas PPARα repressed, targets involved in the cellular glucose
utilization pathway. Our results suggest that one mechanism
whereby PPARβ/δ and PPARα exert reciprocal effects on cellular
glucose uptake occurs through differential regulation of glucose
transporter 4 (GLUT4; Slc2a4) gene transcription.
Results
Generation of MHC-PPARβ/δ mice. To explore the effects of
PPARβ/δ in the heart, we generated transgenic mice with cardiac-specific expression of PPARβ/δ. Three independent lines
of MHC-PPARβ/δ mice were established, with varying levels of
transgene expression — from high physiologic to supraphysiologic — compared with endogenous PPARβ/δ; these were designated low, medium, and high expression (LE, ME, and HE,
respectively; Figure 1A). The lines of MHC-PPARβ/δ mice were
chosen so that the range of transgene expression overlapped with
that of MHC-PPARα lines generated previously; approximately
20-fold (MHC-PPARβ/δ–LE), 50-fold (MHC-PPARβ/δ–ME), and
100-fold (MHC-PPARβ/δ–HE) over levels of the corresponding endogenous nuclear receptor (ref. 19 and data not shown).
MHC-PPARβ/δ transgene expression was confined to the heart
(data not shown). MHC-PPARβ/δ mice were viable, born in the
expected Mendelian ratios, and appeared normal.

The expression of known cardiac PPARα target genes was characterized in hearts of MHC-PPARβ/δ mice compared with nontransgenic (NTG) littermates. The levels of mRNA encoding muscle
carnitine palmitoyltransferase Ib (M-CPT 1b; Cpt1b), which catalyzes the rate-limiting step of mitochondrial import of long-chain
FAs, was induced in MHC-PPARβ/δ–ME and MHC-PPARβ/δ–HE
mice (Figure 1B). In addition, expression of PPARα target genes
involved in mitochondrial (medium-, long-, and very long-chain
acyl-Coenzyme A dehydrogenase [MCAD, Acadm; LCAD, Acadl;
and VLCAD, Acadvl, respectively]) and peroxisomal (acyl-Coenzyme
A oxidase [ACO; Acox1]) FAO and FA dethioesterification (mitochondrial thioesterase 1 [MTE-1; Mte1]) was significantly higher in
MHC-PPARβ/δ–ME and MHC-PPARβ/δ–HE mice than in controls
(Figure 1B). However, only a subset of PPARα target genes (MCAD,
ACO, and MTE-1) were found to be significantly upregulated in the
MHC-PPARβ/δ–LE mice (data not shown).
MHC-PPARβ/δ mice do not develop lipotoxic cardiomyopathy.
MHC-PPARα mice develop cardiac hypertrophy and dysfunction in association with myocardial lipid accumulation and high
FA uptake and utilization rates (19), a phenotype that resembles
the diabetic heart. Hearts from 8-week-old, sex-matched MHCPPARα and MHC-PPARβ/δ mice and corresponding NTG littermates were examined for signs of ventricular hypertrophy
and cardiac dysfunction. As shown previously, the mean biventricular wt/body wt ratio of MHC-PPARα hearts was significantly greater than that of controls (3.9 ± 0.2 versus 3.3 ± 0.1;
P < 0.05), even at low levels of transgene expression. In contrast,
MHC-PPARβ/δ mice did not exhibit cardiac hypertrophy at any
level of transgene expression (Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/
JCI32578DS1). Similar results were obtained whether the ventricular weights were normalized to body weight or tibia length
(Supplemental Figure 1B).
Echocardiography was performed to assess cardiac function of
MHC-PPARβ/δ mice. On standard chow, LV fractional shortening
(FS) was modestly but significantly decreased in MHC-PPARα–
LE mice (50.7% ± 5.4%) compared with controls (58.5% ± 6.7%;
P < 0.05; Figure 2 and Supplemental Table 1). As expected, an
8-week course of HF diet (43% of total calories as fat) resulted in
severe cardiac dysfunction in MHC-PPARα–LE mice, manifest as
a significant decline in LV FS (41.1% ± 5.9%) compared with controls (63.2% ± 5.2%; P < 0.01; Figure 2) as well as systolic and diastolic ventricular dilatation (Supplemental Table 1). In striking
contrast, MHC-PPARβ/δ–LE mice did not exhibit any evidence
of ventricular dysfunction or abnormal chamber enlargement
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Figure 2
Cardiomyopathy develops in MHC-PPARα mice,
but not MHC-PPARβ/δ
mice. (A) Representative M-mode echocardiographic images of the
LV of 8-week-old male
MHC-PPARβ/δ–HE and
MHC-PPARα–LE mice
and NTG littermates after
standard (Std) or HF diet
treatment. (B) Mean percent LV FS (n ≥ 7 per
group) as assessed by
echocardiographic analysis. *P < 0.05 versus NTG;
**P < 0.05 versus NTG
and standard diet–treated
MHC-PPARα–LE.

on standard or HF diets (Figure 2 and Supplemental Table 1).
This latter observation held true even in the MHC-PPARβ/δ–HE
transgenic line (Figure 2).
The absence of a cardiomyopathic phenotype in the MHCPPARβ/δ mice led us to explore the metabolic signatures of lipotoxicity. MHC-PPARβ/δ and MHC-PPARα mice were fed HF chow
for 8 weeks or fasted for 48 hours (to rapidly increase circulating
nonesterified FAs). Levels of myocardial neutral fat were visualized
semiquantitatively by oil red O staining, followed by characterization and quantification of TAG species using electrospray ionization mass spectrometry (ESI/MS). In contrast to MHC-PPARα
mice, MHC-PPARβ/δ hearts did not accumulate abnormal levels
of neutral lipid (Figure 3A). Similar results were obtained following a 48-hour fast (data not shown). Quantification of TAG levels
by ESI/MS demonstrated a significant increase in myocardial TAG
levels in MHC-PPARα mice given HF diet or following a 48-hour
fast compared with controls (Figure 3A). In striking contrast, no
significant difference in myocardial TAG levels was observed in
MHC-PPARβ/δ mice compared with controls following HF diet
or fasting. Taken together with the echocardiographic data, these
results demonstrate that, in contrast to MHC-PPARα mice, MHCPPARβ/δ mice do not develop lipotoxic cardiomyopathy.
Previously, we have shown that neutral lipid accumulation
within the myocytes of MHC-PPARα hearts is associated with
activation of target genes involved in cellular FA uptake and TAG
synthesis. Therefore, we sought to determine whether these gene
regulatory programs were activated in the MHC-PPARβ/δ mice,
given the lack of an observed myocardial lipid phenotype. Expression of genes involved in cellular FA transport was significantly
upregulated in MHC-PPARα–LE mice, including FA transport
protein–1 (FATP-1; Slc27a1; 2.42-fold ± 0.09-fold) and CD36 (Cd36)
(2.13-fold ± 0.09-fold; Figure 3B). In addition, the expression of
genes encoding several key TAG synthesis and lipogenic enzymes,
including glycerol-phosphate-3-acyl transferase (GPAT; Gpam),
3932

acyl-Coenzyme A synthase (ACS; Acsl1), and FA synthase (FAS;
Fasn), was increased in the hearts of MHC-PPARα mice compared
with controls (Figure 3B). The expression of the microsomal transfer protein (MTP; Mttp) gene was also markedly increased in the
MHC-PPARα hearts, presumably as a homeostatic response to
export excess lipid as lipoprotein. In contrast, expression of the FA
uptake, lipogenic, and TAG synthesis gene regulatory programs
was not activated in MHC-PPARβ/δ–HE mouse hearts, with the
exception of a modest increase in MTP mRNA levels. These results
suggest that the abnormal TAG accumulation in MHC-PPARα
mice, but not in MHC-PPARβ/δ mice, is related to differential
activation of gene regulatory programs involved in FA uptake and
TAG synthesis in the former, despite activation of genes involved
in mitochondrial and peroxisomal FAO in both lines (Figure 1B).
MHC-PPARβ/δ mice exhibit increased myocardial glucose uptake and
utilization rates. The hallmarks of metabolic derangements of the
diabetic heart include reduced glucose uptake and utilization, concomitant with increased FA utilization, a fuel utilization profile
that is recapitulated in MHC-PPARα mice (19, 27). To assess myocardial fuel utilization in MHC-PPARβ/δ mice, microPET studies
were performed using 1-11C-glucose and 11C-palmitate as tracers.
Surprisingly, rates of myocardial glucose uptake were significantly
increased in MHC-PPARβ/δ–HE mice, whereas 11C-palmitate in
MHC-PPARβ/δ–HE mice was not different compared with controls
(Figure 4A). Substrate oxidation rates were determined in working
hearts isolated from MHC-PPARβ/δ–HE mice and NTG controls
using [9,10-3H]palmitate and [U-14C]glucose. Consistent with
the microPET results, glucose oxidation rates were significantly
increased in MHC-PPARβ/δ–HE hearts (2,155 ± 59 nmol/min/g
dry wt) compared with controls (1,676 ± 151 nmol/min/g dry wt),
whereas rates of palmitate oxidation were not significantly different (Figure 4B). Consistent with increased reliance on glucose as a
cardiac substrate, myocardial glycogen levels were higher in MHCPPARβ/δ mice than in controls (Figure 4C).

The Journal of Clinical Investigation    http://www.jci.org    Volume 117    Number 12    December 2007

Downloaded on August 12, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/32578

research article
Figure 3
Diet-induced myocardial TAG accumulation in MHC-PPARα mice, but
not MHC-PPARβ/δ mice. (A) Top:
Histologic appearance of ventricular tissue samples from male MHCPPARα–LE and MHC-PPARβ/δ–HE
mice and NTG littermates after 4
weeks of HF diet. Red droplets indicate neutral lipid staining by oil red
O. Bottom: Myocardial TAG levels
determined by ESI/MS following HF
diet or 48-hour fast in male MHCPPARα and MHC-PPARβ/δ mice.
(B) Mean ventricular mRNA levels
for the indicated genes, as determined by RT-PCR analysis, shown
as arbitrary units (AU) normalized to
the value of NTG controls. RNA was
isolated from mouse hearts after 4
weeks of HF diet. The 36B4 signal
was used as internal normalization
control. *P < 0.05 versus NTG.

PPARβ/δ and PPARα exert differential regulation on genes involved
in cardiac glucose metabolism. The striking difference in myocardial
glucose uptake and utilization in MHC-PPARβ/δ compared with
MHC-PPARα mice prompted us to compare expression of genes
involved in cardiac glucose metabolism. We previously found that
the suppressive effects of PPARα on cardiac myocyte glucose utilization occurs at multiple levels including repression of the expression of genes involved in glucose import (GLUT4) and glycolysis
(phosphofructokinase [PFK; Pfk]) (19, 20). In contrast, expression levels of genes encoding GLUT4 and PFK were significantly
increased in hearts of MHC-PPARβ/δ mice compared with controls (Figure 5A). GLUT1 (Slc2a1) gene expression was increased in
MHC-PPARα mouse hearts, possibly as a compensatory response
to the marked downregulation of GLUT4 expression (Figure 5A).
GLUT1 gene expression was not significantly elevated in MHCPPARβ/δ mouse hearts. Levels of hexokinase (HK; Hk2) mRNA
were not significantly altered in either MHC-PPARα or MHCPPARβ/δ mouse hearts (Figure 5A). These results are consistent
with the substrate uptake and flux data and indicate that PPARβ/δ
and PPARα exert distinct effects on gene regulatory programs
involved in cardiac glucose metabolism.
Given that the PPAR isoform–specific gene regulatory patterns
found in the transgenic lines could reflect an artificial pattern as a
result of chronic nuclear receptor overexpression, we next assessed
the effects of activating endogenous PPARα and PPARβ/δ in vivo.
For these experiments, WT (B6CBAF1/J) mice were treated with
the PPARα-specific agonist fenofibrate, the PPARβ/δ-specific agonist L-165,041, or vehicle (DMSO) for 3 days. As observed in the
transgenic mice, treatment with either PPAR agonist resulted in
increased cardiac expression of MCAD, a known PPAR target gene
involved in mitochondrial FAO (Figure 5B). In contrast, mice treated with L-165,041 had increased myocardial GLUT4 and PFK gene
expression, whereas no increase was observed in mice treated with
fenofibrate or vehicle (Figure 5B). Rather, fenofibrate treatment

led to a modest decrease in GLUT4 and PFK mRNA levels. Consistent with the observed difference in myocyte TAG accumulation
in the transgenic models, cardiac CD36 gene expression (based on
quantitative RT-PCR analysis) was induced by fenofibrate but not
by L-165,041 (Figure 5B).
PPAR agonist studies were also performed with rat ventricular cardiac myocytes in culture to determine whether the observed differential metabolic and gene regulatory responses were mediated directly
or via extracardiac effects. Myocytes were treated with fenofibrate,
L-165,041, or vehicle for 48 hours, followed by analysis of gene
expression and 2-deoxyglucose (2-DG) uptake rates. Consistent
with the in vivo findings, basal and insulin-stimulated 2-DG uptake
rates were increased in cells exposed to L-165,041 (Figure 5C), concomitant with increased GLUT4 and PFK gene expression (Supplemental Figure 2), whereas no increase was observed in cells treated
with DMSO or fenofibrate. As also predicted by the in vivo studies,
both fenofibrate and L-165,041 activated MCAD and M-CPT 1b gene
expression (Supplemental Figure 2). Collectively, these results demonstrate that PPAR isoform–specific agonists confer the same differential pattern of metabolic responses observed in hearts of MHCPPARβ/δ and MHC-PPARα mice. Specifically, both PPARβ/δ and
PPARα activated the FAO pathway, whereas activation of PPARβ/δ,
but not PPARα, activated the glucose utilization pathway, and
PPARα, but not PPARβ/δ, activated the FA uptake pathway.
Differential regulation of GLUT4 gene transcription by PPARβ/δ and
PPARα. As an initial step toward characterizing the mechanism
involved in the differential regulation of glucose metabolic genes
by PPARβ/δ and PPARα, transfection studies were performed in
cardiac ventricular myocytes in culture. For these studies, PPARβ/δ
or PPARα expression vectors were cotransfected with a reporter
plasmid containing a firefly luciferase gene driven by 2,240 bp of
the WT human GLUT4 gene promoter region (GLUT4.Luc.2240;
Figure 6A) in the presence or absence of PPARα-specific (fenofibrate) or PPARβ/δ-specific (L-165,041) ligands. GLUT4.Luc.2240
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Figure 4
Increased myocardial glucose utilization in MHC-PPARβ/δ mice.
(A) Left: Standardized uptake value time-activity curves for
11C-palmitate and 11C-glucose into female MHC-PPARβ/δ–HE
and NTG hearts as determined by microPET. Values are
mean ± SD. Right: Representative microPET images at
20 seconds after injection of 11C-palmitate or 11C-glucose.
Images are normalized to total amount of radioactivity injected and body weight. The relative amounts of tracer uptake,
ranging 0–35, are indicated by the color scale. (B) Oxidation
of [9,10-3H]palmitate and [U-14C]glucose was assessed in isolated working hearts of 12-week-old male MHC-PPARβ/δ–HE
and NTG control mice. Bars represent mean oxidation
rates expressed as nanomoles substrate oxidized per gram
dry mass per minute. (C) Glycogen levels were assessed
in mouse hearts from male MHC-PPARα–LE and MHCPPARβ/δ–HE mice and NTG controls. Results are presented
as glucose released from glycogen and normalized to tissue
weight. *P < 0.05 versus NTG.

activity was significantly repressed by PPARα in an exogenous
ligand–independent manner (Figure 6B). In contrast, PPARβ/δ
activated GLUT4.Luc.2240, an effect that was additive with
L-165,041 treatment (Figure 6B). These results, which are consistent with the gene expression studies, demonstrate that PPARα
and PPARβ/δ exert differential transcriptional regulatory effects
on the GLUT4 gene. Interestingly, the PPARα-mediated repressive effect was not influenced by addition of exogenous activator,
whereas the PPARβ/δ-mediated activation was additive with addition of L-165,041. These latter results suggest that endogenous
ligand is limiting for PPARβ/δ and/or that the mechanism whereby PPARα exerts its repressive effect is ligand independent.
We have shown previously that a well-characterized myocyte
enhancing factor 2a (MEF2a) site within the GLUT4 promoter is
necessary for the repressive effect of PPARα on GLUT4 transcription (28). To determine whether this regulatory site is required for
the observed differential transcriptional regulation of GLUT4.
Luc.2240 by PPARα and PPARβ/δ, cotransfection studies were
repeated with a GLUT4 promoter in which the MEF2a site was
deactivated by site-directed mutagenesis (GLUT4.Luc.MEFM;
Figure 6A; ref. 28). The PPARα-mediated repressive effect and the
PPARβ/δ-mediated activation were both abolished with GLUT4.
Luc.MEFM (Figure 6B), demonstrating that the differential transcriptional regulatory effects require the MEF responsive site.
MHC-PPARβ/δ mice are relatively resistant to myocardial ischemia/
reperfusion injury. Previous studies have shown that increased
3934

rates of myocardial FAO and reduced rates of glucose utilization,
as occur in the diabetic heart, sensitize the myocardium to ischemia/reperfusion (I/R) injury (17, 27, 29, 30). Given that the MHCPPARβ/δ mice had increased capacity for myocardial glucose
uptake and oxidation, we sought to determine whether they were
resistant to I/R injury. To this end, MHC-PPARβ/δ, MHC-PPARα,
and WT control mice were subjected to I/R injury by occluding
the left anterior descending artery for 30 minutes, followed by 24
hours of reperfusion. Compared with NTG littermates, the hearts
of MHC-PPARβ/δ mice exhibited significantly less I/R injury, as
determined by measurement of infarcted area relative to area at risk
(IA/AAR; 42.8% ± 3.5% versus 59.9% ± 6.8%; P < 0.05; Figure 7). In
contrast, MHC-PPARα mice had increased IA/AAR compared with
NTG littermates, although the difference was not statistically significant (52.6% ± 4.5% versus 48.3% ± 5.2%; Figure 7). The percent
area at risk relative to the whole heart was not different between
NTG and MHC-PPARα mice (42.4% ± 5.6% and 34.9% ± 3.7%)
or between NTG and MHC-PPARβ/δ mice (49.6% ± 4.8% and
40.0% ± 3.6%; Supplemental Figure 3). Thus, as predicted by the
myocardial fuel utilization pattern, MHC-PPARβ/δ mice are relatively protected against I/R injury.
Discussion
The normal postnatal mammalian heart exhibits remarkable fuel
flexibility, switching between FA and glucose according to nutritional state, physical activity, and diurnal rhythms. This substrate
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Figure 5
PPARα- and PPARβ/δ-specific ligands exert differential
regulation on cardiac metabolic target genes. (A) Mean
ventricular mRNA levels in MHC-PPARα and MHCPPARβ/δ mice, as determined by RT-PCR analysis
(corrected to 36B4 expression), shown as arbitrary units
(AU) normalized to the value of NTG controls. (B) Representative autoradiographs of Northern blot (left) and
RT-PCR (right) analyses performed with RNA isolated
from hearts of WT mice treated with fenofibrate (Feno),
L-165,041 (L1), or DMSO control for 3 days. (C) Rate
of 2-DG uptake (mean ± SEM) determined in neonatal
rat ventricular cardiomyocytes exposed to fenofibrate,
L-165,041, or DMSO for 48 hours. Rates of 2-DG uptake
were determined under basal, insulin-stimulated (Ins), or
cytochalasin B–treated (CytB; to inhibit GLUT4) conditions. *P < 0.05 versus appropriate control.

flexibility is altered in myocardial disease states. For example, hypertensive heart disease is associated with reduced capacity for cardiac
FA utilization (31–33). Conversely, the diabetic heart shifts toward
increased reliance on lipid substrates, leading to excessive rates of
myocardial FA uptake and oxidation, concomitant with reduced
glucose utilization. Evidence is emerging that this loss of cardiac
fuel flexibility contributes to the development of heart failure and
sensitizes the heart to ischemic injury. The metabolic derangements
of the diabetic heart involve gene regulatory programming via
chronic activation of the nuclear receptor PPARα. We have shown
previously that the cardiac phenotype of MHC-PPARα transgenic
mice (19) is strikingly similar to the diabetic heart, providing evidence for a link between derangements in myocardial lipid and
glucose metabolism and cardiac dysfunction. As described herein,
the related nuclear receptor PPARβ/δ exerted remarkably different
actions on cardiac metabolism, including versatility in fuel utilization associated with preservation of cardiac function.
Myocyte lipid accumulation is characteristic of the diabetic heart
(34). The term lipotoxicity has been used to describe the toxic effects
of excessive FA import on cellular function and viability (35). The
diabetic heart exhibits increased FA uptake and myocyte lipid
accumulation, ventricular hypertrophy and dysfunction, derangements in mitochondrial function, increased rates of myocyte apoptosis, and cardiomyopathy characterized by hypertrophy and diastolic/systolic ventricular dysfunction (36–39). The lipid metabolic
derangements of the diabetic heart, as modeled by MHC-PPARα
mice, underscore the impact of chronic PPARα-driven increases in
myocardial FA uptake and utilization. It is believed that despite

increased capacity of diabetic and MHC-PPARα hearts to burn fat,
FAO rates are insufficient to match the high rates of FA import
and esterification, leading to diversion of FA intermediates to toxic
pathways including peroxisomal oxidation and ceramide biosynthesis — both of which lead to the generation of cellular toxins (40).
In this study, we describe the surprising finding that in contrast to
MHC-PPARα mice, MHC-PPARβ/δ mice did not develop myocyte
lipid accumulation or cardiomyopathy, even in the context of a
HF diet. One likely explanation for this striking difference is that
myocardial FA uptake and esterification rates were increased in
MHC-PPARα mice but not in MHC-PPARβ/δ mice. The expression of genes involved in FA uptake (FATP1 and CD36) and triglyceride synthesis (GPAT, ACS, FAS, and MTP) was activated in
the hearts of MHC-PPARα mice but not in MHC-PPARβ/δ mice.
This differential gene regulation was also noted when PPARα and
PPARβ/δ agonists were administered to WT mice. Interestingly,
genes involved in mitochondrial FAO were activated to similar levels in both transgenes. Collectively, these results suggest that the
striking differences in cardiac lipid metabolic phenotype exhibited
by PPARα compared with PPARβ/δ transgenic mice are related to
differential activation of a subset of gene regulatory programs
driving cellular transport and esterification of FA.
In 1963, Randle described the glucose-FA cycle (41). This seminal study demonstrated regulatory crosstalk between the 2 major
fuel utilization pathways in the heart. Specifically, increased flux
through the FAO pathway generates intermediates that confer
reciprocal allosteric repressive effects on the pyruvate dehydrogenase complex, leading to a reduction in glucose oxidation. The
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Figure 6
PPARβ/δ and PPARα differentially regulate GLUT4 gene transcription through a MEF2a-responsive region in the GLUT4 promoter.
(A) GLUT4 promoter reporter constructs (GLUT4.Luc.2240 and
GLUT4.Luc.MEFM) were cotransfected into rat neonatal ventricular
cardiomyocytes with a PPARα or PPARβ/δ expression vector (pBOSPPARα or pCMX-PPARβ/δ) or empty vector control. Cells were
exposed for 48 hours with fenofibrate, L-165,041, or DMSO control.
The GLUT4.Luc.MEFM promoter reporter construct is crossed out to
indicate that the MEF2a binding site has been deactivated by sitedirected mutagenesis. (B) Luciferase activity (mean ± SEM) shown as
relative luciferase units (RLU) corrected for β-galactosidase activity and
normalized to the value of empty expression vector–transfected cells
(n = 12). *P < 0.05 versus empty vector control; **P < 0.01 versus
DMSO; #P < 0.05 versus DMSO.

repression of glucose oxidation by high rates of FAO described by
Randle is one likely mechanism whereby myocardial glucose utilization is reduced in the diabetic heart. In addition, the capacity for
glucose import is constrained in the diabetic heart, which is related, at least in part, to decreased insulin-stimulated translocation
of GLUT4. Evidence is emerging that reduced rates of glucose oxidation contribute to diabetic cardiac dysfunction, particularly in
the setting of I/R injury (17, 27, 29, 30). Previously we have shown
that the PPARα-driven increase in myocardial FAO rates in MHCPPARα mice is linked to diminished rates of glucose uptake and
oxidation and reduced expression of the genes encoding GLUT4
and the glycolytic enzyme PFK (19). This regulatory crosstalk at
the gene expression level is analogous to the rapid posttranslational control of the Randle cycle. In striking contrast to MHC-PPARα
mice, MHC-PPARβ/δ mice exhibited increased rates of myocardial
glucose uptake and utilization. These observations are consistent
with the results of recent studies by others demonstrating that
PPARβ/δ promotes insulin sensitivity in muscle and liver (42, 43).
Our results also demonstrate that, as predicted by the observed
increased capacity for myocardial glucose utilization, the hearts
of MHC-PPARβ/δ mice are resistant to I/R injury.
In addition to PPARα and PPARβ/δ, the heart also expresses low
levels of PPARγ. Recently, the development and characterization of
mice with cardiac-specific overexpression of PPARγ (MHC-PPARγ)
have been described previously (44). Similar to MHC-PPARα mice,

MHC-PPARγ mice have increased expression of CD36, myocyte
lipid accumulation, increased myocardial uptake, and cardiomyopathy (44). This phenotype is similar to that of MHC-PPARα
mice (19, 20). However, unlike MHC-PPARα mice, myocardial
GLUT4 mRNA levels and 2-DG uptake are upregulated in the highexpressing line of MHC-PPARγ mice, a pattern similar to that of
the MHC-PPARβ/δ mice reported here. Together, these findings
suggest that PPARγ shares gene regulatory targets and metabolic
responses in heart with both PPARα and PPARβ/δ. It will be of
significant interest to delineate shared cardiac PPARα and PPARγ
gene targets that are distinct from that of PPARβ/δ.
The observation that MHC-PPARβ/δ hearts utilize glucose
at high rates prompted us to investigate the expression of genes
involved in this pathway. In contrast to the repressive effects of

Figure 7
MHC-PPARβ/δ mice are resistant to myocardial I/R injury. Top: Representative cross-sectional images of the heart after I/R injury followed
by staining with TTC and Evans blue as described in Methods. Blue
staining represents uninjured tissue; orange represents area at risk;
white represents the infarcted region. S, ventricular septum. Bottom:
IA/AAR (mean ± SEM) for male and female MHC-PPARα–LE and
MHC-PPARβ/δ–HE mice and corresponding NTG littermates (n ≥ 15
per group). *P < 0.05 versus NTG.
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PPARα, we found that PPARβ/δ induced the expression of genes
encoding GLUT4 (glucose transport) and PFK (glycolysis) in the
MHC-PPARβ/δ heart. These results do not reflect an artifact of
overexpression, given that the same patterns were observed in vivo
and in cultured myocytes using ligand activation of the endogenous receptors. To gain further insight into this mechanism, we
focused on the reciprocal regulation of GLUT4 gene expression
by PPARα and PPARβ/δ. As predicted by the results of the gene
expression studies, we found that PPARβ/δ and PPARα exerted
differential transcriptional regulation of a GLUT4 gene promoter-reporter, an effect that requires a well-characterized MEF2a
response element rather than a PPAR-responsive element. Indeed,
our analysis of the DNA sequence in the GLUT4 gene 5′-flanking
region did not reveal a PPAR recognition sequence. Collectively,
these findings define one mechanism whereby PPAR isotypes exert
differential regulation on a shared target gene. Future studies
will be necessary to determine whether this is a general paradigm
applicable to other differentially regulated targets, including those
involved in FA uptake and esterification.
Significant evidence supports the notion that therapeutic strategies aimed at reducing myocardial FA uptake and oxidation, while
increasing glucose utilization, will improve the function of the diabetic heart under basal conditions and following ischemic insult.
We show here that in the setting of myocardial I/R injury, cardiacspecific overexpression of PPARβ/δ was cardioprotective: infarct
sizes were smaller in the MHC-PPARβ/δ mice compared with WT
or MHC-PPARα mice. Interestingly, we have found that expression
of PPARα, but not PPARβ/δ, is activated in mouse models of type 2
diabetes, indicating that the ratio of myocardial PPARα to PPARβ/
δ is increased in this disease state (our unpublished observations).
Accordingly, selective activation of PPARβ/δ shows promise as a
therapeutic strategy for diabetic cardiac dysfunction if the same
proves true in humans.
Methods
Materials. The PPARα-specific agonist fenofibrate was obtained from
Sigma-Aldrich. The PPARβ/δ-specific agonist L-165,041 was obtained
from Calbiochem.
Generation of MHC-PPARβ/δ mice. A cDNA construct containing a 1.0-kb
PPARβ/δ cDNA was cloned downstream of the cardiac α-MHC promoter
(clone 26; gift of J. Robbins, The Children’s Hospital Research Foundation,
Cincinnati, Ohio, USA). Transgenic mice were generated by microinjection
of the MHC-PPARβ/δ construct into fertilized 1-cell C57BL/6 × CBA/J F1
embryos in the Washington University Mouse Genetics Core.
Animal studies. Cardiac functional and metabolic end points were analyzed in male and female pairs of MHC-PPARβ/δ and littermate NTG mice
(25–30 g body weight) ranging in age from 8 to 16 weeks. The majority of
data presented in this manuscript represents studies with male mice, with
exceptions noted in the figure legends. In each case, independent analyses
of the opposite gender gave identical results (data not shown). For diet
studies, mice were allowed ad libitum access to HF chow, which provides
43% of the calories from fat (TD 97268; Harlan Teklad). For fasting studies, mice were housed in individual cages at the start of each experiment
and fasted for 48 hours. Control mice were allowed ad libitum access to
standard laboratory rodent chow (diet 5053; Purina Mills Inc.). For agonist studies, mice were treated with DMSO, fenofibrate (100 mg/kg/d),
or L-165,041 (10 mg/kg/d) by oral gavage once daily for 3 days. All animal
studies were conducted in strict accordance with the NIH guidelines for
humane treatment of animals and were approved by the Animal Studies
Committee at Washington University School of Medicine.

Mouse isolated working heart preparation. Mouse working heart perfusions
were performed as previously described (27). Briefly, isolated working
hearts were perfused with Krebs-Henseleit solution containing 5 mM
glucose, 100 μU/ml insulin, and 0.4 mM palmitate. Myocardial FA and
glucose oxidation rates were determined by quantitative collection of
3H O or 14CO produced by hearts perfused with buffer containing [9,102
2
3H]palmitate or [U-14C]glucose.
Isolated neonatal rat ventricular cardiomyocytes. Neonatal rat ventricular
cardiomyocytes were isolated as previously described (45); stimulated
with DMSO, 1 μM fenofibrate, or 10 μM L-165,041 for 48 hours; and
subjected to RNA isolation for Northern blot analysis or assayed for
2-DG uptake rates.
2-DG uptake assay. 2-DG uptake rates were determined in isolated neonatal rat ventricular cardiomyocytes that were stimulated with DMSO,
fenofibrate (1 μM), or L-165,041 (10 μM) for 48 hours. Five hours prior
to the experiment, cells were placed in serum-free medium (Optimem;
Invitrogen). One hour prior to the experiment, 1 U/ml insulin (SigmaAldrich) and 10 μM cytochalasin B (Sigma-Aldrich) were added to intended wells. Cells were incubated for 10 minutes with uptake solution (pH 7.4)
containing [3H]2-DG (2 mCi/ml; American Radiolabeled Nucleotides),
10 μM 2-DG, 140 mM NaCl, 20 mM HEPES, 5 mM KCl, 2.5 mM MgSO4,
and 1 mM CaCl2. The reaction was stopped with ice-cold PBS, cells were
lysed with 50 mM NaOH, lysates were counted by scintillation, and rates
of 2-DG uptake were calculated.
MicroPET studies. Prior to the imaging session, mice were individually
housed and semifasted overnight (allowed access to 1 pellet of rodent
chow). The next morning, mice were fasted for an additional 3 hours
before experiments were performed. MicroPET imaging of 11C-palmitate
and 1-11C-glucose uptake and metabolism was performed on the Focus
120 and 220 (Concord microPET Systems) as previously described (19).
Briefly, regions of interest were placed on the heart of each mouse using
the palmitate image as landmark. Regions of interest were normalized
to animal weight and activity injected to obtain dynamic standardized
uptake value time activity curves. NTG and MHC-PPARβ/δ dynamic standardized uptake values were grouped and averaged. MicroPET images
were similarly standardized.
Echocardiographic studies. Transthoracic M-mode and 2-dimensional echocardiography was performed on conscious mice in the Washington University Mouse Cardiovascular Phenotyping Core using an Acuson Sequoia 256
Echocardiography system (Acuson Corp.) as described previously (46).
RNA analyses. Total RNA was isolated from mouse cardiac ventricles
using the RNAzol method (Tel-Test). Northern blot analysis was performed with QuikHyb (Stratagene) using random-primed 32P-labeled
cDNA clones. Band intensities were quantified using a STORM Phosphorimager (GE Healthcare) and normalized to the expression of 36B4
using ImageQuaNT5.2 software. Real-time quantitative RT-PCR was
performed using the ABI Prism 7500 Sequence Detection System and
reagents supplied by Applied Biosystems. Signal intensity was normalized to expression of 36B4.
Immunoblotting studies. Total cardiac protein was prepared as previously described (47). Western blot analyses were performed using a rabbit
polyclonal PPARβ/δ (H-74) antibody (Santa Cruz Biotechnology Inc.) and
a rabbit polyclonal anti-GLUT4 antibody (gift of M. Mueckler, Washington
University School of Medicine). Detection was performed by measuring the
chemiluminescent signal as assayed by SuperSignal Ultra (Pierce).
Histologic analyses. Mouse hearts were collected, and a midventricular
cross-sectional slice of myocardium was immersed in Tissue-Tek OCT
Compound (Sakura Finetek USA Inc.) and snap-frozen using Cytocool II
(Richard-Allan Scientific) in a cryomold for sectioning. Sections were
stained with oil red O to detect intracellular neutral lipid accumulation.
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Myocardial TAG levels. ESI/MS was used to quantitate myocardial TAG
levels as previously described (48). Briefly, lipids were extracted from mouse
hearts using a modified Bligh and Dyer technique, and subsequent analysis
of TAG species was performed in the positive ion mode.
Glycogen measurements. Mouse cardiac tissue from 8-week-old male and
female MHC-PPARβ/δ and NTG mice was pulverized under liquid nitrogen and homogenized in a 0.3 M perchloric acid solution. The muscle
extract was then assayed with and without amyloglucosidase digestion
(Sigma-Aldrich) in 50 mM sodium acetate (pH 5.5) and 0.02% BSA. Resulting changes in absorption at 340 nM were compared with a standard of
0–80 μmol glucose. Results are presented as glucose released from glycogen
and normalized to tissue weight.
Promoter studies. GLUT4 promoter reporter constructs (GLUT4.Luc.2240;
kindly provided by J. Pessin, University of Iowa, Iowa City, Iowa, USA; and
GLUT4.Luc.MEFM) were cotransfected into rat neonatal ventricular cardiomyocytes with a PPARα or PPARβ/δ expression vector (pBos-PPARα or
pCMX-PPARβ/δ) or empty vector control (pEFBOS or pCMX). Cells were
stimulated for 48 hours with PPARα-specific (fenofibrate) or PPARβ/δspecific (L-164,041) agonists or DMSO control. Luciferase activity in relative luciferase units was corrected for SV 40 β-galactosidase (500 ng/ml)
and normalized to the value of empty vector control–transfected cells.
Myocardial I/R studies. Mice were anesthetized (ketamine/xylazine), surgically prepped and ventilated on a Harvard rodent respirator. After exposing
the heart, the pericardium was removed, and a 9-0 polypropylene suture
with a U-shaped needle was passed under the left anterior descending
artery. The suture was tied over a piece of PE-10 tubing to occlude the left
anterior descending artery for 30 minutes. After the occlusion period, the
PE-10 tube was carefully removed to allow for reperfusion. The chest was
then closed and the mouse recovered. After 24 hours of reperfusion, the
mouse was again anesthetized and injected subcutaneously with heparin
(1 U/g). The abdominal cavity was opened, and a heparin/KCL mixture
was injected into the inferior vena cava to stop the heart. The mouse was
then bled out by cutting the renal artery. The carotid arteries were ligated,
the descending aorta was cannulated, and the heart was perfused with a
phosphate buffer followed by 1% TTC (Fisher). The left anterior descend1. Zimmet, P., Alberti, K.G., and Shaw, J. 2001. Global
and societal implications of the diabetes epidemic.
Nature. 414:782–787.
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ing artery was then reoccluded at the original site, and 1% Evans Blue Dye
(Sigma-Aldrich) was perfused. The heart was removed and frozen at –20°C
for 1 hour, sliced into 5 pieces, and fixed in 4% neutral buffered formalin
overnight at 4°C. After 24 hours in formalin, the heart slices were weighed.
An image of each side of all slices was taken using a Canon Power Shot A80
digital camera. Each image was analyzed using the Image Tool software
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slice and normalizing to slice weight. Next, a region at risk was calculated
as the portion of the LV absent of blue dye. The percent of infarcted tissue
(white area) within this region of risk was calculated (see Figure 7).
Statistics. Data were analyzed by 2-tailed Student’s t test or ANOVA and
presented as mean ± SEM. A P value less than 0.05 was considered statistically significant.
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